Prepared for professional clients and institutional/qualified investors. It is not to be distributed to or relied on by retail clients

AVIVA INVESTORS - EUROPEAN EQUITY FUND (SHARE CLASS I)

AS AT 31 MAY 2015

FUND MANAGER

Mark Denham Since 10 March 2012 BENCHMARK MSCI Europe TR EUR SHARE CLASS CURRENCY EUR ΝΔν EUR 232.1698 AUM EUR 187.80m INDUSTRY CODES ISIN LU0160772918 SEDOL: 9003251 PRIGRI1 LX Bloomberg: MEXID: CUEGI LAUNCH DATE

21 January 2003 MINIMUM INVESTMENT

EUR 500.000.00

FEES

Management Fee: 0.75% p.a. SETTLEMENT

T + 3

NAV CALCULATION 18:00 CET

OBJECTIVE

To increase the value of the Shareholder's investment over time.

HISTORY

Change of Fund Manager on 1 July 2011

March 2012: Change of Fund Manager.

April 2015: Change of Benchmark previously MSCI Europe Excluding UK. Performance

shown incorporates this change. MANAGEMENT COMPANY

Aviva Investors Luxembourg SA 2 rue du Fort Bourbon

Luxembourg

L-1249

INVESTMENT ADVISOR

Aviva Investors Global Services

Limited CUSTODIAN

J.P. Morgan Bank Luxembourg S A

AUDITOR PricewaterhouseCoopers Société coopérative

LEGAL FORM

Sub fund of Aviva Investors SICAV (Luxembourg UCITS)

HIGHLIGHTS

- Over the month the Fund outperformed the benchmark by +2.45%, with an overall absolute return of +3.85%
- Stakes in Ryanair and Syngenta added value
- Oxford Biomedica and Bone Therapeutics were key detractors

PERFORMANCE VS BENCHMARK (%) - 5 YEARS OR SINCE LAUNCH



COMMENTARY

European equities struggled to make much headway in May. Investors were unsettled by a bond market sell-off early in the month. As the month progressed, sentiment deteriorated as the focus shifted to growing uncertainty as to the outcome of talks between Greece and its international creditors.

Relative

Fund holdings Ryanair and Syngenta performed strongly in May. Shares in the Irish budget airline Ryanair climbed after it announced a jump in annual earnings due to the impact of low fuel prices and increasing passenger numbers. This news was particularly well received by investors because results from Easyjet, a rival low-cost carrier, proved disappointing.

Swiss agricultural chemicals group Syngenta saw its shares soar after it rejected an unsolicited takeover bid from US agricultural seeds and chemicals group Monsanto. Elsewhere, several of the Fund's holdings in smaller health care-related companies, including 4D Pharma, Genmab and Biocartis, did well. However, after a period of strong share price appreciation, fund holdings Oxford Biomedica and Bone Therapeutics fell as investors took profits.

PERFORMANCE (%)

	Cumulative					Annualised					
	1 M	3 M	6 M	YTD	1 Y	3 Y	5 Y	Since launch	1 Y	3 Y	5 Y
Fund	3.85	10.03	25.62	25.31	29.51	106.72	104.37	132.17	29.51	27.39	15.36
Benchmark	1.37	3.80	17.06	19.61	18.99	91.62	90.77	149.71	18.99	24.21	13.78
Relative	2.45	6.00	7.31	4.77	8.84	7.88	7.13	-7.03	8.84	2.56	1.39
Source: Aviva Investors/Lipper as Basis: Mid to mid. gross income re		es. in Euro									

Past performance is not a guide to the future

TOP 10 UNDERWEIGHTS (%)

BP Plc

BAT



TOP 10 OVERWEIGHTS (%)

SAP Unilever Drc Nv Temenos Group Advanced Onc. Plc Roche Hldg. Ag-Gen. Syngenta Ag Deutsche Boerse Genmab Compagnie Fin. Rich. Anima Holding




+140

-0.07

+3.17

-3 55

-0.58



3 70

Source: Aviva Investors/Aladdin as at 31 May 2015 Basis: Excludes cash & unassigned



AVIVA INVESTORS - EUROPEAN EQUITY FUND (SHARE CLASS I)


AS AT 31 MAY 2015



IMPORTANT INFORMATION


expressed are those of Aviva Investors Global Services Limited ("Aviva Investors"). They should not be viewed as indicating any guarantee of return from an investment managed by Aviva Past performance is not a guide to the future. The value of an investment and any income from it may go down as well as up and the investor may not get back the original amount invested. This document should not be taken as a recommendation or offer by anyone in any jurisdiction in which such an offer is not authorised or to any person to whom it is unlawful to make . such an offer or solicitation. The legal documentation and the subscription investment is made. The underlying holdings of the fund should be considered in order to establish an appropriate minimum holding period. The Prospectus and Key Investor Information Document (KIID), are available, together with the Report and Accounts of the SICAV, free of charge from Aviva Investors Luxembourg, 2 rue du Fort Bourbon 1st Floor.L-1249 Luxembourg, Grand Duchy of Luxembourg R.C.S. Luxembourg B25708, Aviva Investors, No.1 Poultry, London EC2R 8EJ or relevant office below. The Prospectus is available in English and German. Where a sub fund of the SICAV is registered for public distribution in a jurisdiction, a KIID in the official language of that jurisdiction will be available. The Prospectus, the KIIDs the Annual and Semi-Annual Reports are available free of charge in Austria from Raiffeisen Bank International AG, Am Stadtpark 9, 1030 Vienna the paying agent and in Switzerland, from the representative and paying agent BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zurich, Switzerland. In Spain, copies of the Prospectus and KIID together with the Report and Accounts are available free of charge from the offices of distributors in Spain. The UCITS is authorised by the CNMV with registration number 7. When this document is distributed in or from the DIFC, it is distributed by Aviva Investors Global Services Limited Representative Office, Office 108, Al Fattan Currency House, DIFC, Dubai, UAE. Regulated by the Dubai Financial Services Authority with Reference Number F001481. This document is intended for Persons of the type specified in the DFSA's Rules as "Professional Clients and must not be delivered to, or relied Investors Global Services Limited, registered in England No. 1151805. Registered Office: No. 1 Poultry, London EC2R 8EJ. Authorised and regulated in the UK by the Financial Conduct Authority and a member of the Investment Association. Relative Return rather than simply the Fund return less Benchmark Return. [(1 + Fund Return / 100) / (1 + Benchmark Return / 100) -1] * 100.15/SC0129/12072015

ABSOLUTE COUNTRY BREAKDOWN (%)



Source: Aviva Investors/Aladdin as at 31 May 2015 Basis: Excludes cash & unassigned

RELATIVE COUNTRY BREAKDOWN (%)



Source: Aviva Investors/Aladdin as at 31 May 2015 Basis: Excludes cash & unassigned

ABSOLUTE TOP 10 HOLDINGS (%)




Source: Aviva Investors/Aladdin as at 31 May 2015 Basis: Excludes cash & unassigned

RISK STATISTICS

RISK TYPE	VALUE	GLOSSARY
Beta	0.86	A measure of the fund volatility in comparison to the market. A beta of less than 1 implies that the fund will be less volatile than the market whilst a beta greater than 1 implies the fund is more volatile than the market.
Information Ratio	0.63	A measure of the manager's ability to generate excess and consistent returns relative to the funds benchmark. The greater the IR, the more consistent a manager is.
Volatility	9.19	A measure of the funds dispersion of returns. A higher volatility implies that a fund's return is spread over a larger range of values whilst a lower volatility implies that a funds return is spread over a smaller range of values.
Tracking Error	4.00	A measure of how closely the fund follows its benchmark. A passive fund should have a tracking error close to zero, while an actively managed fund would normally have a higher tracking error.
Sharpe Ratio	2.67	A measure of the fund's risk-adjusted performance. The greater the fund's Sharpe ratio, the better its risk-adjusted performance has been.
Source: Aviva Investors/Lipper as at 3	1 May 2015	


Source: Aviva Investors/Lipper as at 31 May 2015 Basis: Three year ex-poste (monthly data) in Euro Risk Free Rate: One Month EURIBOR, in Euro

ABSOLUTE SECTOR BREAKDOWN (%)



Source: Aviva Investors/Aladdin as at 31 May 2015 Basis: Excludes cash & unassigned

RELATIVE SECTOR BREAKDOWN (%)



Source: Aviva Investors/Aladdin as at 31 May 2015 Basis: Excludes cash & unassigned